PEPGEN Stock Rises After Positive Trial Results

PEPGEN (PEPG) saw a significant boost in its stock value on Thursday, following the release of results from a Phase 1 clinical trial. This research focused on PGN-EDODM1 as a potential treatment for myotonic dystrophy type 1, which is a genetic muscle disorder leading to progressive weakness and stiffness, among other symptoms.

The standout news from this trial is that it successfully met all its objectives. Notably, there was an impressive mean splicing correction observed after just one dose of PGN-EDODM1, surpassing previously reported results for DM1 patients. The company mentioned it plans to share more detailed findings from this study in the first quarter of 2026.

In tandem with this positive announcement regarding the clinical trial, Pepgen has announced a public stock offering. They are set to sell 31.25 million shares of PEPG at a price of $3.20 each, which will yield approximately $100 million in gross revenue. Furthermore, the underwriter has a 30-day window to acquire an additional 4,687,500 shares at the same price. Pepgen intends to funnel these funds into further research and development initiatives, including clinical trials for Freedom-DM1 and Freedom2-DM1, as well as general operational costs.

Pepgen Stock Performance Today

Following a robust rally of 36.41% the previous day, Pepgen shares surged by 124.06% in pre-market trading on Thursday. However, it’s worth noting that the stock has dipped by 29.82% and 69.39% over the past year. There’s been intense trading activity, with around 53 million shares exchanged compared to the typical daily average of about 570,000 shares.

Current Analyst Sentiment on Pepgen Stocks

On Wall Street, analysts are leaning towards a consensus of medium buys for Pepgen, with four buy ratings and one sell rating in the past three months. Additionally, the average target price for PEPG shares is set at $6.80, indicating a potential upside of approximately 155.64%.